DermTech, Inc.
NASDAQ: DMTK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Bret Christensen
- Employees
- 206
- Headquarters
- La Jolla, United States
- IPO year
- 2017
- Market cap
- $3.3M
- Website
- https://www.dermtech.com
Loading DMTK…
Loading profile data…Frequently asked questions about DMTK
What does DermTech, Inc. (DMTK) do?
DermTech, Inc., a molecular diagnostics firm headquartered in La Jolla, California, specializes in creating and bringing to market advanced, non-invasive genomic tests. Operating within the United States, their innovative solutions facilitate the diagnosis of various dermatological issues, including skin cancer, inflammatory conditions, and age-...
Where does DMTK trade?
DermTech, Inc. (DMTK) trades on the NASDAQ Capital Market.
What sector is DMTK in?
DermTech, Inc. (DMTK) operates in the Healthcare sector, specifically in the Medical - Diagnostics & Research industry.
Who is the CEO of DermTech, Inc.?
Bret Christensen is the chief executive officer of DermTech, Inc. (DMTK).
Where is DermTech, Inc. headquartered?
DermTech, Inc. is headquartered in United States.
Does DMTK pay a dividend?
DermTech, Inc. (DMTK) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did DMTK go public?
DermTech, Inc. (DMTK) completed its initial public offering in 2017.